Rakuten Medical
Rakuten Medical Raises $100M Series F | Photoimmunotherapy Cancer Treatment
Rakuten Medical Closes $100M for Cancer Treatment
Rakuten Medical, developing photoimmunotherapy treatments for cancer, has raised $100 million in Series F funding led by TaiAx.
Key Highlights
- Currently in global Phase 3 trial
- Novel photoimmunotherapy approach
- Late-stage clinical development
Company Overview
Rakuten Medical is developing a precision cancer treatment using photoimmunotherapy that selectively destroys cancer cells while preserving healthy tissue.
Company Info
Investors (2)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free